Physicians
Diagnosis to treatment in days, not weeks
ASPYRE’s comprehensive lung panel simultaneously analyzes DNA and RNA from blood or tissue in a single assay, enabling straightforward, precise identification of all NCCN guideline recommended genomic biomarkers associated with approved targeted therapies for non-small cell lung cancer (NSCLC).
Fast time to treatment
ASPYRE enables the analysis of comprehensive panels of biomarkers from blood or tissue at extremely high sensitivity in a matter of hours. Patients can go from diagnosis to treatment in days instead of weeks.
Ultra-sensitive
With the ability to detect as little as one molecule of mutated DNA or RNA1, ASPYRE is up to 10 times more sensitive than NGS and 50 times more sensitive than single-gene PCR tests.
Actionable results
ASPYRE accelerates and simplifies analysis by eliminating the noise from genomic data, ensuring accuracy for the markers that are of interest to enable more confident decision-making.
Reduced sample requirements
ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumor content, compared to 20% or 30% for most competing assays.
1Single-copy detection of somatic variants from solid and liquid biopsy, Scientific Reports, Mar 16: 10.1038/s4 1598-021-85545-3
Featured resources & publications


